NEXTBio Capital Management LP
AUSTIN, TX · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 13, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$234.4M2026 Q3
Positions25
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.67.6%
What Changed This Quarter?
Top Holdings
PTGX
Protagonist Therapeutics
13.2%
STTK
Shattuck Labs
10.8%
CMPS
COMPASS Pathways
9.4%
RYTM
Rhythm Pharmaceuticals
5.4%
VOR
Vor Biopharma
5.1%
PHVS
Pharvaris N.V.
5.0%
XENE
Xenon Pharmaceuticals
4.9%
ZBIO
Zenas BioPharma
4.9%
New / Increased
5 new · 5 increased
Entera BioNEW
Entera Bio
3.6%
KRSANEW
Korsana Biosciences
2.4%
Blossomhill T…NEW
Blossomhill Therapeutics
2.0%
ADRXNEW
Adarx Pharmaceuticals
0.9%
GLUENEW
Monte Rosa Therapeutics
0.6%
PHVS
N.V. Pharvaris
5.0%
+244.8%
XENE
Xenon Pharmaceuticals
4.9%
+69.3%
COGT
Cogent Biosciences
2.4%
+35.8%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.